GLP-1 microdosing: what it is, and what evidence actually supports it

'Microdosing' has become a catch-all term online for taking a GLP-1 at doses below what the FDA label prescribes — sometimes to stretch a limited supply, sometimes to reduce side effects, sometimes just to save money. It's worth separating the honest evidence from the marketing before deciding whether it's a real strategy or a workaround with real trade-offs.

What 'microdosing' actually means in practice

There's no single agreed-upon definition, but in practice it usually refers to one of two things: staying at a low titration step (like 0.25 mg or 0.5 mg semaglutide) far longer than the labeled schedule calls for, rather than progressing to the studied maintenance dose, or drawing a fraction of a standard dose from a compounded vial using a syringe rather than an FDA-labeled pen. Neither of these is the same as simply following your prescriber's individualized titration pace, which is a normal, medically supervised adjustment — the term specifically describes going well below labeled dosing on a sustained basis, often self-directed. For the actual FDA-labeled doses, concentrations, and volumes this compares against, see our dosing chart.

What the dose-response evidence actually shows

The trials that established these drugs' efficacy are themselves dose-response data, and they're informative here. STEP 2 tested semaglutide at both 1.0 mg and 2.4 mg doses and found the higher, labeled dose produced meaningfully greater weight loss¹. SURMOUNT-1 tested tirzepatide at 5, 10, and 15 mg and found a clear dose-response relationship, with higher doses producing larger average reductions². That pattern is about as close to a direct answer as the evidence gets: doses meaningfully below the studied maintenance range are associated with meaningfully less weight loss on average. Separately, the FDA has approved lower-dose formulations for specific, studied purposes — a 25 mg oral semaglutide dose was tested for weight management in the OASIS 4 trial as a genuine, formally studied lower-dose option — which is a very different thing from an unstudied, self-directed microdose drawn from a vial³.

What genuinely isn't studied

There is no published trial evidence on the specific practice of staying indefinitely at a fraction of the labeled dose to stretch supply, nor on drawing partial doses from compounded vials for cost-saving 'microdosing' regimens. That's a real evidence gap, not a hidden endorsement — the absence of a trial showing harm is not the same as evidence of safety or effectiveness at an arbitrary fraction of a labeled dose. If your actual goal is fewer side effects, the evidence-backed path is a slower, prescriber-guided titration through the labeled schedule — see semaglutide dosing and titration and tirzepatide dosing and titration — not an indefinite plateau at a low dose decided outside that process.

Where the practice tends to come from

Microdosing is most common among people using compounded GLP-1s, where a vial and syringe make partial dosing physically easy in a way an FDA-labeled pen doesn't. That's worth pairing with the broader compounded-pharmacy vetting checklist in is compounded semaglutide legit?, since a provider encouraging unsupervised partial dosing to save money is a different posture than one working within a labeled or clinically individualized schedule. It's also worth reading alongside how much does semaglutide cost and how much does tirzepatide cost if cost is the real driver — there may be a legitimate lower-cost path that doesn't involve unsupervised dose-splitting.

A handful of providers now sell low-dose GLP-1 as a named product with its own intake rather than leaving you to split a vial. Auren Rx runs the most fully specified one we've read, at $149 a month for semaglutide and $250 for tirzepatide with no commitment. That is a better arrangement than improvising — a clinician is at least aware of the schedule you're actually on — but it changes nothing about the evidence. A microdose program with its own page and its own price table is still a program built on a dose no randomized trial has tested. It is also worth checking what the low dose actually costs, because the assumption that less drug costs less money does not hold: SkinnyRx charges the same for its microdose line as for full dose at every term the two share, and the microdose floor is the higher of the two — $229 against $199 on semaglutide, $319 against $299 on tirzepatide — because the microdose plan stops at eight months while the full-dose one runs to twelve.

The honest bottom line

If a low, sustained dose is something you and your prescriber decide on together — because it's genuinely working for you, or because side effects at higher doses aren't tolerable — that's a legitimate, individualized clinical decision, not 'microdosing' in the self-directed sense the term usually implies. What the evidence doesn't support is treating an arbitrary fraction of a labeled dose, chosen for cost or convenience without clinical guidance, as equivalent to the therapy that was actually studied. This is general information, not medical advice — any change to your dose should go through your prescriber.